



PHYTOTECH MEDICAL

ASX RELEASE

6 February 2015

CLINICAL-DEVELOPMENT PATH OF BUCCAL AND ORAL PRODUCTS

Highlights

- Phytotech Medical is developing an oral capsule and buccal patch therapeutic products containing a combination of Cannabinoid (CBD) and Tetrahydrocannabinol (THC) for treating various clinical indications
- Favorable regulatory path due to;
 - Both the THC and CBD compounds are currently used in commercially registered products and as such are proven to be safe and efficacious
 - The buccal and oral products in development with Yisum are based on proprietary technologies already implemented in commercial products, significantly lowering the regulatory hurdles

PhytoTech Medical Limited ACN: 601 236 417
Physical: Suite 25, 145 Stirling Highway, Nedlands WA 6009
Postal: P.O. Box 3144, Nedlands WA 6009
Ph: (08) 9389 3150 Web: www.phytotechmed.com

For personal use only



ASX RELEASE CONTINUED

- Decreased regulatory requirements expected to lead to a significantly shorter and less expensive development pathway

Phytotech Medical Limited (ASX:PYL), the Australian owned Medical Grade Cannabis (MGC) company and the first MGC company to list on the Australian Stock Exchange, is pleased to provide an update on the research and development of its MGC based therapeutic delivery systems for administering Medical Grade Cannabis (MGC).

The clinical-development regulatory route for both the oral capsule, which demonstrated in pre-clinical studies enhanced bioavailability of THC or CBD and the buccal muco-adhesive patch is expected to be shorter and simpler to register, when compared to a new drug entity.

Both cannabinoids to be used in the products; Cannabinoid (CBD) and Tetrahydrocannabinol (THC), are currently used in commercially registered products and have been prescribed to patients for an extensive period of time. As such both have been proven to be safe and efficacious.

The products in development are based on Yissum's proprietary technologies, implemented in various commercial products.

Using active ingredients, which are already registered and implemented in technologies is expected to markedly decrease the regulatory requirements resulting in a significantly shorter and less expensive pathway.

Managing Director of Phytotech Boaz Wachtel commented: "Our agreement with Yissum enables us to harness existing technologies and



ASX RELEASE CONTINUED

cannabinoids, which have previously been commercialised, thereby decreasing the development period. Whilst there is never zero risk in biotech development and unexpected delays can occur in clinical trials we are expecting that the clinical development path for the products currently in progress will be significantly shorter than the market average.”

Under the agreement with Yisum, Phytotech is utilizing Yisum’s state-of-the-art technologies to develop an oral capsule and buccal patch containing a combination Tetrahydrocannabinol (THC) and Cannabinoid (CBD) for treating a variety of clinical indications.

The technology, which will be able to overcome the effects of first pass metabolism will markedly increase the oral absorbance of the active cannabinoid and in pre-clinical studies, the formulations of CBD and THC for use in the oral capsule showed significantly enhanced bioavailability.

-Ends-

For more information please contact

Boaz Wachtel, Managing Director

+61 8 9389 3150

info@phytotechmed.com

For media enquiries

Media & Capital Partners

Asher Moses, Associate Director

+61 438 008 616

Asher.moses@mcpartners.com.au



About PhytoTech Medical Limited

PhytoTech Medical is a medical cannabis company, which aims to commercialise Medical Grade Cannabis (MGC) and high potential cannabis based therapeutics products to the rapidly growing international market with regulated medical cannabis laws. With research facilities located in Israel, a global leader in medical cannabis research, the Company is strategically positioned to become a key player in the global MGC market.

The Company is focused on the research, development and commercialisation of products for administering MGC, and on new treatments utilising MGC therapeutic components for various medical conditions. In addition, the Company aims to grow proprietary strains of MGC in California, Uruguay and other jurisdictions.

PhytoTech has entered into an exclusive research and licensing agreement with Yissum, the prestigious Research Development and technology transfer Company of Hebrew University in Jerusalem, Israel. Yissum was founded in 1964 to protect and to commercialise the Hebrew University's intellectual property. Products based on Hebrew University technologies that have been commercialised by Yissum currently generate US\$2 Billion in annual sales. Ranked among the top technology transfer companies in the world, Yissum has registered over 8,500 patents covering 2,400 inventions; has licensed out 750 technologies and has spun out 90 companies. Yissum's partners span



ASX RELEASE CONTINUED

the globe and include names such as Microsoft, Johnson & Johnson, Syngenta, Monsanto, Roche, Novartis, Merck, Teva and many more.

Using proprietary technology, PhytoTech's vision is to administer ground breaking health benefits of cannabinoids in oral preparations, vapor form, and other routes of administration in safe and effective ways.

<http://www.phytotechmed.com/>